Longitudinal performance in cervical cancer screening of an HPV mRNA assay for detection of severe lesions occurring up to seven years later

VALGENT 4

J Bonde & D Ejegod

Italian consensus on cervical cancer screening in hpv vaccinated woman

P Giorgi Rossi, M T Sandri, L Mariani & F Carozzi

Primary hrHPV population screening for cervical cancer in the Netherlands

K M Holtzer-Goor, E Brouwer, N van der Veen & S A van Dijk

Integrating HPV-screening and HPV vaccination in Central and Eastern Europe

M Poljak

Core elements of the new HPV-based cervical cancer screening programme in Italy

G Ronco

VALGENT2 contribution towards hpv-primary screening in scotland

K Cuschieri & R Bhatia

Xpert HPV: Basis and key results in best trials

L Denny, R Saidu & L Kuhn

HPV screening: DNA- versus RNAbased HPV Tests

T Iftner

Slovenian HPV Prevalence Study and VALGENT 3 framework

M Poljak & A Oštrbenk

The BD Onclarity HPV assay: Key data pointing to clinical validity

M H Stoler & T C Wright Jr

Primary HPV screening in the US with the Cobas® assay

A C Cohen & W K Huh

Experiences with the use of HPV testing in cervical cancer screening in Sweden

J Dillner & M Elfström

Self-sampling to reach non-participating women

J Bonde & D Ejegod

HPV assays validated for primary cervical cancer screening

M Arbyn & P Hillemanns

HPV testing on self-samples: the evidence of Today

M Arbyn, S Smith & P Castle

HPV-based cervical cancer screening in US

N Wentzensen & M Schiffman

Australia on-track to be the first country to achieve cervical cancer elimination

K Canfell, M Hall, K Simms, M Smith & M Saville

Interview Marc Arbyn

M Arbyn

HPV DNA or HPV E6/E7 mRNA assays?